Spruce Biosciences (SPRB) to Release Quarterly Earnings on Thursday

Spruce Biosciences (NASDAQ:SPRB) is expected to announce its Q4 2025 results before the market opens on Thursday, March 12th. Analysts expect the company to announce earnings of ($9.1575) per share for the quarter. Parties can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Friday, March 13, 2026 at 9:30 AM ET.

Spruce Biosciences Stock Performance

SPRB opened at $57.54 on Thursday. Spruce Biosciences has a 52-week low of $4.28 and a 52-week high of $240.00. The firm has a market cap of $61.57 million, a P/E ratio of -0.68 and a beta of 3.62. The business’s fifty day moving average is $73.76 and its 200-day moving average is $74.07.

Analyst Ratings Changes

A number of equities research analysts have issued reports on SPRB shares. HC Wainwright reiterated a “buy” rating and set a $200.00 price objective (down from $220.00) on shares of Spruce Biosciences in a research note on Thursday, February 19th. Citizens Jmp set a $259.00 price target on shares of Spruce Biosciences in a report on Tuesday, November 11th. Wall Street Zen cut shares of Spruce Biosciences from a “hold” rating to a “sell” rating in a research note on Saturday, December 27th. Oppenheimer initiated coverage on shares of Spruce Biosciences in a research report on Tuesday, December 23rd. They set an “outperform” rating and a $283.00 price objective for the company. Finally, Leerink Partners raised Spruce Biosciences from a “market perform” rating to an “outperform” rating and set a $160.00 target price on the stock in a report on Wednesday, December 3rd. Four analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $187.90.

Hedge Funds Weigh In On Spruce Biosciences

A number of institutional investors have recently added to or reduced their stakes in the stock. SkyView Investment Advisors LLC acquired a new stake in Spruce Biosciences in the fourth quarter valued at approximately $261,000. State Street Corp acquired a new position in shares of Spruce Biosciences during the fourth quarter worth $558,000. Superstring Capital Management LP bought a new position in shares of Spruce Biosciences in the 4th quarter valued at $1,057,000. Geode Capital Management LLC bought a new position in shares of Spruce Biosciences in the 4th quarter valued at $1,109,000. Finally, Caligan Partners LP acquired a new stake in shares of Spruce Biosciences during the 4th quarter valued at $1,787,000. 91.71% of the stock is currently owned by institutional investors and hedge funds.

Spruce Biosciences Company Profile

Spruce Biosciences, Inc is a clinical-stage biopharmaceutical company dedicated to developing therapies for rare endocrine and dermatological disorders. Headquartered in San Diego, California, Spruce focuses on conditions with significant unmet medical needs, employing a precision medicine approach to identify and advance treatment candidates through late-stage clinical trials.

The company’s lead asset, tildacerfont, is an oral corticotropin-releasing factor type 1 (CRF1) receptor antagonist being evaluated for the treatment of congenital adrenal hyperplasia (CAH), a genetic disorder characterized by insufficient cortisol production and excess androgen levels.